(Total Views: 564)
Posted On: 11/24/2020 2:05:46 AM
Post# of 716
$RLFTF NEURORX AND RELIEF ANNOUNCE INITIAL SUCCESSFUL RESULTS FROM EXPANDED ACCESS USE OF RLF-100™ (AVIPTADIL) IN PATIENTS WITH CRITICAL COVID-19 AND SEVERE COMORBIDITY: 72% SURVIVAL SEEN IN ICU PATIENTS
https://relieftherapeutics.com/newsblog/neuro...u-patients
https://relieftherapeutics.com/newsblog/neuro...u-patients
(0)
(0)
$MJ
Scroll down for more posts ▼
